3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Targeting Cbx3/HP1γ Induces LEF-1 and IL-21R to Promote Tumor-Infiltrating CD8 T-Cell Persistence

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Immune checkpoint blockade (ICB) relieves CD8 + T-cell exhaustion in most mutated tumors, and TCF-1 is implicated in converting progenitor exhausted cells to functional effector cells. However, identifying mechanisms that can prevent functional senescence and potentiate CD8 + T-cell persistence for ICB non-responsive and resistant tumors remains elusive. We demonstrate that targeting Cbx3/HP1γ in CD8 + T cells augments transcription initiation and chromatin remodeling leading to increased transcriptional activity at Lef1 and Il21r. LEF-1 and IL-21R are necessary for Cbx3/HP1γ-deficient CD8 + effector T cells to persist and control ovarian cancer, melanoma, and neuroblastoma in preclinical models. The enhanced persistence of Cbx3/HP1γ-deficient CD8 + T cells facilitates remodeling of the tumor chemokine/receptor landscape ensuring their optimal invasion at the expense of CD4 + Tregs. Thus, CD8 + T cells heightened effector function consequent to Cbx3/HP1γ deficiency may be distinct from functional reactivation by ICB, implicating Cbx3/HP1γ as a viable cancer T-cell-based therapy target for ICB resistant, non-responsive solid tumors.

          Related collections

          Most cited references82

          • Record: found
          • Abstract: found
          • Article: not found

          Subsets of exhausted CD8+ T cells differentially mediate tumor control and respond to checkpoint blockade

          T cell dysfunction is a hallmark of many cancers, but the basis for T cell dysfunction and the mechanisms by which antibody blockade of the inhibitory receptor PD-1 (anti-PD-1) reinvigorates T cells are not fully understood. Here we show that such therapy acts on a specific subpopulation of exhausted CD8 + tumor-infiltrating lymphocytes (TILs). Dysfunctional CD8 + TILs possess canonical epigenetic and transcriptional features of exhaustion that mirror those seen in chronic viral infection. Exhausted CD8 + TILs include a subpopulation of ‘progenitor exhausted’ cells that retain polyfunctionality, persist long term and differentiate into ‘terminally exhausted’ TILs. Consequently, progenitor exhausted CD8 + TILs are better able to control tumor growth than are terminally exhausted T cells. Progenitor exhausted TILs can respond to anti-PD-1 therapy, but terminally exhausted TILs cannot. Patients with melanoma who have a higher percentage of progenitor exhausted cells experience a longer duration of response to checkpoint-blockade therapy. Thus, approaches to expand the population of progenitor exhausted CD8 + T cells might be an important component of improving the response to checkpoint blockade.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma

            Treatment of cancer has been revolutionized by immune checkpoint blockade therapies. Despite the high rate of response in advanced melanoma, the majority of patients succumb to disease. To identify factors associated with success or failure of checkpoint therapy, we profiled transcriptomes of 16,291 individual immune cells from 48 tumor samples of melanoma patients treated with checkpoint inhibitors. Two distinct states of CD8 + T cells were defined by clustering, and associated with patient tumor regression or progression. A single transcription factor, TCF7 , was visualized within CD8 + T cells in fixed tumor samples and predicted positive clinical outcome in an independent cohort of checkpoint-treated patients. We delineated the epigenetic landscape and clonality of these T cell states, and demonstrated enhanced anti-tumor immunity by targeting novel combinations of factors in exhausted cells. Our study of immune cell transcriptomes from tumors demonstrates a strategy for identifying predictors, mechanisms and targets for enhancing checkpoint immunotherapy. Single cell analysis of immune cells from melanoma uncovers a TCF7+ memory-like state in the cytotoxic T cell population, and demonstrates its association with a positive outcome
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Defining CD8(+) T cells that provide the proliferative burst after PD-1 therapy.

              Chronic viral infections are characterized by a state of CD8(+) T-cell dysfunction that is associated with expression of the programmed cell death 1 (PD-1) inhibitory receptor. A better understanding of the mechanisms that regulate CD8(+) T-cell responses during chronic infection is required to improve immunotherapies that restore function in exhausted CD8(+) T cells. Here we identify a population of virus-specific CD8(+) T cells that proliferate after blockade of the PD-1 inhibitory pathway in mice chronically infected with lymphocytic choriomeningitis virus (LCMV). These LCMV-specific CD8(+) T cells expressed the PD-1 inhibitory receptor, but also expressed several costimulatory molecules such as ICOS and CD28. This CD8(+) T-cell subset was characterized by a unique gene signature that was related to that of CD4(+) T follicular helper (TFH) cells, CD8(+) T cell memory precursors and haematopoietic stem cell progenitors, but that was distinct from that of CD4(+) TH1 cells and CD8(+) terminal effectors. This CD8(+) T-cell population was found only in lymphoid tissues and resided predominantly in the T-cell zones along with naive CD8(+) T cells. These PD-1(+)CD8(+) T cells resembled stem cells during chronic LCMV infection, undergoing self-renewal and also differentiating into the terminally exhausted CD8(+) T cells that were present in both lymphoid and non-lymphoid tissues. The proliferative burst after PD-1 blockade came almost exclusively from this CD8(+) T-cell subset. Notably, the transcription factor TCF1 had a cell-intrinsic and essential role in the generation of this CD8(+) T-cell subset. These findings provide a better understanding of T-cell exhaustion and have implications in the optimization of PD-1-directed immunotherapy in chronic infections and cancer.
                Bookmark

                Author and article information

                Contributors
                Journal
                Front Immunol
                Front Immunol
                Front. Immunol.
                Frontiers in Immunology
                Frontiers Media S.A.
                1664-3224
                06 October 2021
                2021
                : 12
                : 738958
                Affiliations
                [1] 1 Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, United States
                [2] 2 Institute of Cell and Neurobiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin and Berlin Institute of Health , Berlin, Germany
                [3] 3 Division of Gynecologic Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, United States
                [4] 4 Department of Human Nutrition, Food, and Exercise, Virginia Tech , Blacksburg, VA, United States
                [5] 5 Center for Cancer Research, National Cancer Institute , Bethesda, MD, United States
                [6] 6 Center for Discovery and Innovation, Hackensack University Medical Center , Nutley, NJ, United States
                [7] 7 Nazarbayev University School of Medicine , Nur-Sultan, Kazakhstan
                [8] 8 Cancer Research Institute, Beth Israel Deaconess Medical Center, Harvard Medical School , Boston, MA, United States
                Author notes

                Edited by: William L. Redmond, Earle A. Chiles Research Institute, United States

                Reviewed by: Elena Jachetti, Istituto Nazionale dei Tumori (IRCCS), Italy; Xin Yu, Amgen, United States

                *Correspondence: To-Ha Thai, tthai@ 123456bidmc.harvard.edu

                This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology

                †Present address: Ngoc Ha, Department of Physiology, Anatomy and Genetics, Oxford University, Oxford, Oxfordshire, United Kingdom Ngan K. Tran, Center for Drug Discovery, Department of Pharmaceutical Sciences, Northeastern University, Boston, MA, United States

                ‡These authors have contributed equally to this work

                Article
                10.3389/fimmu.2021.738958
                8549513
                a7218369-69a3-47fd-b025-02a29d2f92a6
                Copyright © 2021 Le, Ha, Tran, Newman, Esselen, Dalrymple, Schmelz, Bhandoola, Xue, Singh and Thai

                This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

                History
                : 09 July 2021
                : 08 September 2021
                Page count
                Figures: 7, Tables: 0, Equations: 0, References: 82, Pages: 18, Words: 8922
                Categories
                Immunology
                Original Research

                Immunology
                cbx3/hp1γ,lef-1,il-21 receptor,cd8+ t-cell persistence,ovarian cancer,melanoma
                Immunology
                cbx3/hp1γ, lef-1, il-21 receptor, cd8+ t-cell persistence, ovarian cancer, melanoma

                Comments

                Comment on this article